PA Biotechnology

What PA Biotechnology does

PA Biotechnology Industry Trade Inc. is a Turkish B2B biotechnology startup headquartered in EGE Teknopark, Bornova/Izmir, founded in December 2023. The company develops in vitro tissue and disease models for ethical product safety testing, with a service and product portfolio that spans cytotoxicity, genotoxicity, skin irritation (OECD 439), skin corrosion (OECD 431), phototoxicity (OECD 498 using RhE models), wound healing assays, and bespoke 2D/3D cell culture and organ-on-chip model development. Its primary customer verticals are cosmetics and personal care manufacturers (lead), followed by pharmaceutical and chemical companies that require OECD-aligned safety data and animal-free alternatives for regulatory compliance. Underlying technology centers on reconstructed human epidermis (RhE) models, supplemented by microfluidic system development and alginate-hydrogel-based preservation methods (supported via TUSEB projects) to maintain cell viability during RhE transport. The team of 6–10 combines PhD-level scientists from Ege University with a Notified Body-experienced QA/RA specialist and a senior CMO with 15 years of commercial experience. The business is a hybrid of fee-for-service contract testing and a developing productized test kit business. Current revenue is project-based B2B testing with quote-based pricing; two proprietary skin irritation test kits (standard and microfluidic) are upcoming or in development and are expected to diversify into recurring product revenue. The company has no institutional venture capital to date and has been bootstrapped through Turkish government and EU-linked grants (TÜBİTAK 1512 BİGG, KOSGEB, Turkey Development Fund, Competitive Sectors Program), with a single disclosed capital raise of $30,000 from the Turkey Development Fund in March 2024.

Name

PA Biotechnology

Legal name

PA Biotechnology Industry Trade Inc.

Website

https://pa-biotech.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

PA Biotechnology is a Turkish B2B biotechnology startup that offers in vitro safety testing services and develops animal-free skin irritation, corrosion, and phototoxicity test kits using reconstructed human epidermis (RhE) models for cosmetics, pharmaceutical, and chemical industry clients.

Ownership category

akta.pro rank

Product category

Biotechnology Testing Services

NAICS

Testing Laboratories and Services (541380), Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Services-Testing Laboratories (8734), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

In Vitro Toxicology (Cell-based/Organ-on-chip) (HLAGAFAJ)

akta.pro secondary industry

Cell-Based & Potency Assays (Bioassays) (HLAGADAH)

Keywords

• In vitro testing services
• Skin irritation assays
• Tissue model development
• Animal-free safety testing
• Biotechnology contract research

Headquarters

HQ city

Bornova

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Contract Testing Services: B2B testing services for pharmaceutical, cosmetic, chemical, and biotechnological companies requiring safety validation of their products through cytotoxicity, genotoxicity, phototoxicity, skin irritation, and skin corrosion tests
2. Custom In Vitro Model Development: Development of tailored in vitro models (2D/3D cell cultures, organ-on-chip systems) for specific client research and development projects in drug discovery, biomaterial testing, and disease modeling
3. In Vitro Test Kits: Planned future revenue stream from proprietary in vitro skin irritation test kits, including upcoming microfluidic system-based kits

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

PA Biotechnology provides B2B in vitro safety testing services for the cosmetic, pharmaceutical, chemical, and biotechnological industries using reconstructed human epidermis (RhE) models and standardized OECD test methods (439, 431, 498). The company also develops custom 2D/3D cell culture and organ-on-chip models for client-specific drug discovery, biomaterial testing, and disease modeling projects, and is developing proprietary in vitro skin irritation test kits including a microfluidic variant.

Product overview

PA Biotechnology operates as a service and product company offering a portfolio of in vitro testing services and developing test kit products for the cosmetic, pharmaceutical, and biotechnology industries. The core service offerings include Cytotoxicity Testing Services, Skin Irritation Testing Services (OECD 439), Custom In Vitro Model Development, In Vitro Skin Wound Healing (Scratch) Assay, In Vitro Diabetic Wound Healing Assay, OECD 431: In Vitro Skin Corrosion Test, OECD 498: In Vitro Phototoxicity Test, Genotoxicity Testing Service, and Phototoxicity Testing Services. The company is also developing two product lines: the In Vitro Skin Irritation Test Kit (upcoming) and In Vitro Skin Irritation Test Kits using Microfluidic Systems (in development). All services utilize advanced biotechnological methods including reconstructed human epidermis (RhE) models to provide ethical, animal-free alternatives for product safety testing.

Differentiator

Problem solved

Functional benefit

Products and services

• Cytotoxicity Testing Services In vitro testing service that evaluates the toxic effects of substances on cultured cells to assess product safety for pharmaceutical, cosmetic, chemical, and biotechnological products.
• Skin Irritation Testing Services (OECD 439) In vitro skin irritation testing service using advanced models that simulate human skin to assess a product's potential to cause irritation upon skin contact, ensuring compliance with global regulations.
• Custom In Vitro Model Development Custom development of 2D and 3D cell culture platforms, organ-on-chip systems, and customized in vitro models that simulate biological processes for drug discovery, biomaterial testing, toxicity analysis, and disease modeling.
• In Vitro Skin Wound Healing (Scratch) Assay Laboratory-based method evaluating wound healing process by observing how skin cells migrate across a damaged surface, testing the wound-healing effects of biomaterials, drugs, or cosmetic products.
• In Vitro Diabetic Wound Healing Assay Specialized assay simulating impaired wound healing seen in diabetic patients using skin cells exposed to diabetic-mimicking conditions to evaluate potential treatments for chronic diabetic wounds.
• OECD 431: In Vitro Skin Corrosion Test Standardized in vitro test method using reconstructed human epidermis (RHE) models to assess the corrosion potential of substances on human skin, determining irreversible damage for regulatory compliance.
• OECD 498: In Vitro Phototoxicity Test Using the RhE Method Standardized in vitro test using reconstructed human epidermis (RhE) models to assess phototoxic potential of substances upon exposure to ultraviolet light, critical for cosmetic and pharmaceutical safety assessment.
• Genotoxicity Testing Service Testing service identifying substances that may cause genetic mutations or damage using cutting-edge methodologies to assess potential genetic impact of pharmaceutical, cosmetic, chemical, and biotechnological products.
• Phototoxicity Testing Services Comprehensive phototoxicity testing service evaluating whether products may cause adverse effects when exposed to light, particularly ultraviolet radiation, using state-of-the-art techniques and realistic light exposure scenarios.
• In Vitro Skin Irritation Test Kit Test kit product for evaluating skin irritation potential, designed to deliver reliable and precise results for the cosmetics industry.

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• EGE Teknopark (EGE D-TECH Project)coreStrategic or Co-development PartnerParticipated in EGE D-TECH DEMO DAY organized by EGE Teknopark with financial support from the European Union and Republic of Türkiye under the Competitive Sectors Program of the Ministry of Industry and Technology. The project aims to develop innovative solutions in advanced biotechnology and in vitro test systems.
• EBIOPHASE Laboratory (EBioPhase)minorStrategic or Co-development PartnerFounding team member Pelin Ilhan conducted research at EBIOPHASE Laboratory focusing on spinal cord injury models as part of the M-ERA.NET project. Current team member Umut Doğu Seçkin works as Laboratory Research Assistant in the 3D Biomaterials and Biointerfaces Laboratory (EBioPhase) at Ege University, involved in in vitro models and test kit development projects.
• Ege UniversitycoreStrategic or Co-development PartnerCore team members (CEO Pelin Ilhan and CTO Aylin Sendemir) have academic affiliations with Ege University. The company collaborates with university laboratories including the 3D Biomaterials and Biointerfaces Laboratory and operates within the EGE Teknopark ecosystem.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• TissUse GmbH: Berlin-based organ-on-chip and multi-organ microphysiological systems company. Directly comparable to PA Biotechnology's R&D investment in organ-on-chip and microfluidic-based in vitro test kits and custom model development.
• CellGenix: Supplier of GMP-grade cell culture media, reagents, and human primary cells used in 3D tissue and in vitro assay workflows. Adjacent peer given overlap with the cell/tissue culture reagent backbone of PA Biotechnology's RhE and 2D/3D assay pipeline.

Direct peers

• BIOAlternatives: In vitro toxicology CRO specializing in cytotoxicity, genotoxicity, skin/eye irritation, and phototoxicity assays. Closely comparable to PA Biotechnology's mix of cytotoxicity, genotoxicity, and phototoxicity service offerings for cosmetic and chemical clients.
• MatTek Life Sciences: Maker of the EpiDerm reconstructed human epidermis (RhE) tissue model and other in vitro toxicology assays. Directly comparable to PA Biotechnology because both provide OECD-aligned skin irritation/corrosion/phototoxicity testing built around RhE and 3D tissue models for cosmetics, chemicals, and pharma.
• EpiSkin (Episkin SA, L'Oréal): L'Oréal-owned provider of reconstructed skin models for in vitro safety and efficacy testing, with deep roots in OECD-validated assays. Mirrors PA Biotechnology's core offering of standardized RhE-based skin safety testing services and kits.
• SkinEthic (L'Oréal R&I): Develops reconstructed human epidermis and other epithelia for in vitro toxicology and irritation testing. Comparable to PA Biotechnology's RhE platform for OECD 431/439/498-aligned cosmetic safety evaluations.

Broad incumbents

• Eurofins Scientific: Global testing services conglomerate with a strong cosmetics, chemicals, and pharma safety portfolio including in vitro and GLP testing. Comparable as the dominant incumbent PA Biotechnology would compete against for outsourced safety testing work.
• Charles River Laboratories: Large CRO providing preclinical and toxicology services across pharma, chemicals, and cosmetics. Relevant incumbent benchmark for PA Biotechnology's cytotoxic/genotoxic/irritation services and for clients looking to consolidate preclinical safety work.
• Labcorp Drug Development (incl. Covance): Major clinical and preclinical laboratory services network offering toxicology, safety, and specialty testing. Relevant incumbent reference for the pharma and chemical safety testing segments PA Biotechnology serves.
• SGS Life Sciences: Global testing and certification group with a Life Sciences division covering cosmetics, chemicals, and pharma safety testing. Comparable to PA Biotechnology as a broad-based testing services incumbent competing for outsourced in vitro safety contracts.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/p-a-biotechnology

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PA Biotechnology